AMRN - All good things to those who wait...

8 авг. 2019 г.

Been following this company's progress for over ten years. It is truly remarkable what they have been through to get to where they are now. Bottomline, Vascepa is a blockbuster in the making with incredibly compelling and unprecedented outcomes based clinical trial results which will make this standard of care to a large subset of our population. What is even more compelling is this is a highly pharmacoeconomic argument being a relatively inexpensive therapy with profound positive preventative cardiovascular characteristics and basically zero side-effects. Very surprised one of big pharma has not taken their shot at this company yet, perhaps simply waiting for the final checkmark in the expanded label from the FDA in the Fall. Amazing thing is, they are already approaching a $500 million annual revenue run-rate with limited label and sales force, so projecting $2.5-5 Billion molecule for this with expanded label, expanded sales, and incredibly strong outcomes based clinical data is very possible...would suggest company should/could get taken out at multiple of current stock price over the coming year.

9 авг. 2019 г.

Note

Obviously, the Adcom news is a surprise in that the FDA couldn't get their act in gear to get this set up or even hint that they were going to do it sooner. But truly, given the landmark nature of the REDUCE-IT results, it is the right thing to do hold an Adcom meeting. Usually the questions brought up leading into the Adcom creates negative tension/sentiment on the stock because air is given to all concerns, so that will certainly keep a lid on the stock from roaring higher. With that said, today's move down to the $14 level seems like a massive over-reaction and a tremendous opportunity to get on board for the long haul. Buy fear!